Rosie Smith is currently serving as Legal Counsel at CEPI (Coalition for Epidemic Preparedness Innovations) since February 2023. Previously, Rosie held various positions at Burness Paull LLP from August 2015 to August 2022, including Senior Solicitor in Employment, where responsibilities included advising clients across sectors and drafting legal agreements. Rosie also gained experience as an Employee Relations Manager (Solicitor) on secondment at SSE plc from March 2019 to March 2020, assisting stakeholders with employee relations and legal matters. Educational credentials include a forthcoming course at Harvard Law School in Patent Law and Global Health, a Postgraduate Diploma in Professional Legal Practice from The University of Edinburgh, an LLB with French Language from the University of Glasgow, a Diplôme d'Etudes Universitaires Françaises from Université Jean Moulin, and academic achievements from Preston Lodge High School.
CEPI (Coalition for Epidemic Preparedness Innovations)
2 followers
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines against future epidemics. Prior to COVID-19, CEPI’s work focused on developing vaccines against the Ebola Virus Disease, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus. It has over 20 vaccine candidates against these pathogens in development. CEPI has also invested in new platform technologies for rapid vaccine development against unknown pathogens (Disease X). During the COVID-19 pandemic, CEPI initiated multiple programmes to develop vaccines against SARS-CoV-2 and its variants with a focus on speed, scale, and access. These programmes leverage the rapid response platforms developed by CEPI’s partners prior to the emergence of COVID-19, as well as new collaborations. The aim is to advance clinical development of a diverse portfolio of safe and effective COVID-19 candidates and to enable fair allocation of these vaccines worldwide through COVAX. CEPI’s 5-year plan lays out a $3.5 billion roadmap to compress vaccine development timelines to 100 days, develop a broadly protective vaccine against COVID-19 and other Betacoronaviruses, and create a “library” of vaccine candidates for use against known and unknown pathogens. The plan is available at www.endpandemics.cepi.net